- Home
- OTLK vs NTWK Comparison
OTLK vs NTWK Comparison
Compare OTLK & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- NTWK
- Stock Information
- Founded
- OTLK 2010
- NTWK 1997
- Country
- OTLK United States
- NTWK United States
- Employees
- OTLK N/A
- NTWK N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- NTWK Computer Software: Prepackaged Software
- Sector
- OTLK Health Care
- NTWK Technology
- Exchange
- OTLK Nasdaq
- NTWK Nasdaq
- Market Cap
- OTLK 48.3M
- NTWK 50.8M
- IPO Year
- OTLK 2016
- NTWK 1998
- Fundamental
- Price
- OTLK $2.34
- NTWK $4.14
- Analyst Decision
- OTLK Strong Buy
- NTWK
- Analyst Count
- OTLK 5
- NTWK 0
- Target Price
- OTLK $9.60
- NTWK N/A
- AVG Volume (30 Days)
- OTLK 1.1M
- NTWK 48.5K
- Earning Date
- OTLK 08-14-2025
- NTWK 09-29-2025
- Dividend Yield
- OTLK N/A
- NTWK N/A
- EPS Growth
- OTLK N/A
- NTWK N/A
- EPS
- OTLK N/A
- NTWK 0.02
- Revenue
- OTLK $1,505,322.00
- NTWK $64,127,568.00
- Revenue This Year
- OTLK N/A
- NTWK N/A
- Revenue Next Year
- OTLK $407.74
- NTWK N/A
- P/E Ratio
- OTLK N/A
- NTWK $204.93
- Revenue Growth
- OTLK N/A
- NTWK 9.18
- 52 Week Low
- OTLK $0.87
- NTWK $2.14
- 52 Week High
- OTLK $8.32
- NTWK $4.60
- Technical
- Relative Strength Index (RSI)
- OTLK 63.83
- NTWK 56.08
- Support Level
- OTLK $1.95
- NTWK $3.96
- Resistance Level
- OTLK $2.14
- NTWK $4.33
- Average True Range (ATR)
- OTLK 0.17
- NTWK 0.31
- MACD
- OTLK 0.03
- NTWK -0.05
- Stochastic Oscillator
- OTLK 77.62
- NTWK 43.21
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About NTWK NetSol Technologies Inc. Common Stock
NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.